Adagrecoxib CAS 2326521-71-3
2326521-71-3
Pharmaceutical Grade
99%
SHANGHAI
airuike
25kg/Cardboard Drum
Yes
2025-07-20
api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceKRAS G12C Inhibitor MRTX849 is an orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration MRTX849 covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
MRTX-849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favourable drug-like properties, modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits KRAS-dependent signalling. MRTX-849 demonstrated pronounced tumour regression in 17 of 26 (65%) KRASG12C-positive cell line- and patient-derived xenograft models from multiple tumour types, and objective responses have been observed in patients with KRASG12C-positive lung and colon adenocarcinomas[1].
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform being developed by Mirati Therapeutics for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Class: non-kinase; Treatment: KRAS(G12C) NSCLC; Other name: MRTX849; Elimination half-life: 24 h; Protein binding = 98.3%Basic Info-
Product Name:
Adagrasib
Other Name:MRTX849;MRTX-849;MRTX 849;2-PIPERAZINEACETONITRILE, 4-[7-(8-CHLORO-1-NAPHTHALENYL)-5,6,7,8-TETRAHYDRO-2-[[(2S)-1-METHYL-2-PYRR;2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-;2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile;MRTX849(Adagrasib);Adagrasib/MRTX-849;Adagrasib;4-[7-(8-CHLORO-1-NAPHTHALENYL)-5,6,7,8-TETRAHYDRO-2-[[(2S)-1-METHYL-2-PYRR
CAS No.:2326521-71-3
Molecular Formula:C32H35ClFN7O2
InChIKeys:PEMUGDMSUDYLHU-ZEQRLZLVSA-N
Molecular Weight:604.12
Exact Mass:603.2524792
UNII:8EOO6HQF8Y
NCI Thesaurus Code:C157493
Color/Form:White to yellow
Categories:
Characteristics-
Density:
1.295±0.06 g/cm3(Predicted)
Boiling Point:860.2±75.0 °C(Predicted)
PKA:9.31±0.40(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals
-
Location:
Huangdao District, Qingdao City, Shandong Province (formerly Room 606-2, Building 1, No. 10 Beijing Road, Jiaonan City)
-
Payment Terms:
TT against copy of documents,D/P,D/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
15 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2023
Company Certificates-
Credit rating certificate
-
Hazardous Chemicals Business License
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
